0001193125-22-243702.txt : 20220913 0001193125-22-243702.hdr.sgml : 20220913 20220913160557 ACCESSION NUMBER: 0001193125-22-243702 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 16 CONFORMED PERIOD OF REPORT: 20220912 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20220913 DATE AS OF CHANGE: 20220913 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ALNYLAM PHARMACEUTICALS, INC. CENTRAL INDEX KEY: 0001178670 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 770602661 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-36407 FILM NUMBER: 221240807 BUSINESS ADDRESS: STREET 1: 675 WEST KENDALL STREET STREET 2: HENRI A. TERMEER SQUARE CITY: CAMBRIDGE STATE: MA ZIP: 02142 BUSINESS PHONE: (617) 551-8200 MAIL ADDRESS: STREET 1: 675 WEST KENDALL STREET STREET 2: HENRI A. TERMEER SQUARE CITY: CAMBRIDGE STATE: MA ZIP: 02142 FORMER COMPANY: FORMER CONFORMED NAME: ALNYLAM PHARMACEUTICALS INC DATE OF NAME CHANGE: 20020724 8-K 1 d397120d8k.htm 8-K 8-K
false 0001178670 0001178670 2022-09-12 2022-09-12

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): September 13, 2022 (September 12, 2022)

 

 

Alnylam Pharmaceuticals, Inc.

(Exact name of Registrant as Specified in Its Charter)

 

 

 

Delaware   001-36407   77-0602661

(State or Other Jurisdiction

of Incorporation)

  

(Commission

File Number)

  

(IRS Employer

Identification No.)

675 West Kendall Street

Henri A. Termeer Square

Cambridge, MA 02142

(Address of principal executive offices, including zip code)

(617) 551-8200

(Registrant’s telephone number, including area code)

Not Applicable

(Former name or former address, if changed since last report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

  

Trading

Symbol(s)

  

Name of each exchange

on which registered

Common Stock, $0.01 par value per share   ALNY   The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company  ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐

 

 

 

Item 8.01

Other Events.

On September 12, 2022, the Company issued a press release relating to the commencement of its proposed offering of convertible senior notes due 2027 to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Convertible Note Offering”). On September 13, 2022, the Company issued a press release relating to the pricing of the Convertible Note Offering. Copies of the press releases relating to the Convertible Note Offering are filed as Exhibits 99.1 and 99.2, respectively, to this Current Report on Form 8-K and are incorporated by reference herein.

This Current Report on Form 8-K, including the exhibits attached hereto, does not constitute an offer to sell or the solicitation of an offer to buy any securities, and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offering, solicitation or sale would be unlawful.

 

Item 9.01

Financial Statements and Exhibits.

(d) Exhibits

 

Exhibit
No.

   

Description

99.1    Press release relating to the Convertible Note Offering issued by Alnylam Pharmaceuticals, Inc. on September 12, 2022.
99.2    Press release relating to the Convertible Note Offering issued by Alnylam Pharmaceuticals, Inc. on September 13, 2022.
104    Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: September 13, 2022

 

ALNYLAM PHARMACEUTICALS, INC.
By:  

/s/ Jeffrey V. Poulton

  Jeffrey V. Poulton
  Executive Vice President, Chief Financial Officer
 EX-99.1 2 d397120dex991.htm EX-99.1 EX-99.1

Exhibit 99.1

 

Contacts:

Alnylam Pharmaceuticals, Inc.

    LOGO

Christine Regan Lindenboom

(Investors and Media)

+1-617-682-4340

Josh Brodsky

(Investors)

+1-617-551-8276

Alnylam Announces Proposed Offering of $900 Million Convertible Senior Notes

CAMBRIDGE, Mass. — September 12, 2022 — Alnylam Pharmaceuticals, Inc. (“Alnylam”) (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it has commenced a private offering of $900 million aggregate principal amount of convertible senior notes due 2027 (the “notes”) to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). In connection with this offering, Alnylam expects to grant the initial purchasers of the notes an option to purchase, for settlement within a 13-day period beginning on, and including, the date on which the notes are first issued, up to an additional $135 million aggregate principal amount of the notes. The offering of the notes is subject to market and other conditions and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

The notes will be senior, unsecured obligations of Alnylam, will accrue interest payable semi-annually in arrears and will mature on September 15, 2027, unless earlier converted, redeemed or repurchased. Noteholders will have the right to convert their notes in certain circumstances and during specified periods. Alnylam will settle conversions by paying or delivering, as applicable, cash, shares of its common stock, par value $0.01 per share (“common stock”), or a combination of cash and shares of its common stock, at Alnylam’s election. The notes will be redeemable, in whole or in part (subject to certain limitations), for cash at Alnylam’s option at any time, and from time to time, on or after September 20, 2025 and on or before the 21st scheduled trading day immediately preceding the maturity date, if the last reported sale price per share of Alnylam’s common stock exceeds 130% of the conversion price for a specified period of time. The redemption price will be equal to the principal amount of the notes to be redeemed, plus accrued and unpaid interest, if any, to, but excluding, the redemption date. The interest rate, initial conversion rate and other terms of the notes will be determined at the pricing of the offering.

In connection with the pricing of the notes, Alnylam expects to enter into privately negotiated capped call transactions with one or more of the initial purchasers or their respective affiliates or other financial institutions (the “option counterparties”). The capped call transactions are expected generally to reduce potential dilution to Alnylam’s common stock upon conversion of any notes and/or offset any potential cash payments Alnylam is required to make in excess of the principal amount of converted notes, as the case may be, with such reduction and/or offset subject to a cap.

Alnylam has been advised that, in connection with establishing their initial hedges of the capped call transactions, the option counterparties or their respective affiliates expect to purchase shares of Alnylam’s common stock and/or enter into various derivative transactions with respect to Alnylam’s common stock concurrently with or shortly after the pricing of the notes. This activity could increase (or reduce the size of any decrease in) the market price of Alnylam’s common stock or the notes at that time. In addition, the option counterparties or their respective affiliates may modify their hedge positions by entering into or unwinding various derivatives with respect to Alnylam’s common stock and/or purchasing or selling Alnylam’s common stock or other securities of Alnylam in secondary market transactions following the pricing of the notes and prior to the maturity of the notes (and are likely to do so during any observation period related to a conversion of notes). This activity could cause or avoid an increase or a decrease in the market price of Alnylam’s common stock or the notes, which could affect the ability of holders to convert the notes and, to the extent the activity occurs following conversion or during any observation period related to a conversion of notes, it could affect the amount and value of the consideration that holders will receive upon conversion of the notes.

Alnylam intends to use a portion of the net proceeds from the offering to pay the cost of the capped call transactions. If the initial purchasers exercise their option to purchase additional notes, Alnylam expects to use a portion of the net proceeds from the sale of the additional notes to enter into additional capped call transactions. In addition, Alnylam intends to use approximately $762.0 million of the net proceeds from the offering to repay borrowings and accrued and unpaid interest, and to pay the prepayment premium, under and terminate its current credit agreement, and the remainder of the net proceeds for general corporate purposes.

The notes will be offered only to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act. The offer and sale of the notes and any shares of common stock issuable upon conversion of the notes have not been, and will not be, registered under the Securities Act or any other securities laws, and the notes and any such shares cannot be offered or sold absent registration or except pursuant to an applicable exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and any other applicable securities laws.

This press release does not constitute an offer to sell, or the solicitation of an offer to buy, the notes or any shares of common stock issuable upon conversion of the notes, nor will there be any sale of the notes or any such shares, in any state or other jurisdiction in which such offer, sale or solicitation would be unlawful.

About Alnylam Pharmaceuticals

Alnylam (Nasdaq: ALNY) has led the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of people afflicted with rare and prevalent diseases with unmet need. Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful, clinically validated approach yielding transformative medicines. Since its founding 20 years ago, Alnylam has led the RNAi Revolution and

continues to deliver on a bold vision to turn scientific possibility into reality. Alnylam’s commercial RNAi therapeutic products are ONPATTRO® (patisiran), GIVLAARI® (givosiran), OXLUMO® (lumasiran), AMVUTTRA® (vutrisiran) and Leqvio® (inclisiran) being developed and commercialized by Alnylam’s partner, Novartis. Alnylam has a deep pipeline of investigational medicines, including multiple product candidates that are in late-stage development. Alnylam is executing on its “Alnylam P5x25” strategy to deliver transformative medicines in both rare and common diseases benefiting patients around the world through sustainable innovation and exceptional financial performance, resulting in a leading biotech profile. Alnylam is headquartered in Cambridge, MA.

Alnylam Forward Looking Statements

Various statements in this release concerning Alnylam’s future expectations, plans and prospects, including, without limitation, statements regarding: whether Alnylam will offer and issue the notes and the terms of the notes; the anticipated use of the net proceeds from the offering; expectations regarding the effect of the capped call transactions; expectations regarding actions of the option counterparties and their respective affiliates; and whether the capped call transactions will become effective, constitute forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Actual results and future plans may differ materially from those indicated by these forward-looking statements as a result of various important risks, uncertainties and other factors, including, without limitation: the direct or indirect impact of the COVID-19 global pandemic or any future pandemic on Alnylam’s business, results of operations and financial condition and the effectiveness or timeliness of Alnylam’s efforts to mitigate the impact of the pandemic; the potential impact of the recent leadership transition on Alnylam’s ability to attract and retain talent and to successfully execute on its “Alnylam P5x25” strategy; Alnylam’s ability to discover and develop novel drug candidates and delivery approaches; the pre-clinical and clinical results for its product candidates; actions or advice of regulatory agencies and Alnylam’s ability to obtain and maintain regulatory approval for its product candidates, including patisiran and vutrisiran, as well as favorable pricing and reimbursement; successfully launching, marketing and selling its approved products globally; delays, interruptions or failures in the manufacture and supply of its product candidates or its marketed products; obtaining, maintaining and protecting intellectual property; Alnylam’s ability to successfully expand the indication for ONPATTRO, AMVUTTRA or OXLUMO in the future; Alnylam’s ability to manage its growth and operating expenses through disciplined investment in operations and its ability to achieve a self-sustainable financial profile in the future without the need for future equity financing; Alnylam’s ability to maintain strategic business collaborations; Alnylam’s dependence on third parties for the development and commercialization of certain products, including Novartis, Sanofi, Regeneron and Vir; the outcome of litigation; the potential impact of current and the risk of future government investigations; and unexpected expenditures; as well as those risks more fully discussed in the “Risk Factors” filed with Alnylam’s most recent Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (“SEC”) and in its other SEC filings. In addition, any forward-looking statements represent Alnylam’s views only as of today and should not be relied upon as representing its views as of any subsequent date. Alnylam explicitly disclaims any obligation, except to the extent required by law, to update any forward-looking statements.

EX-99.2 3 d397120dex992.htm EX-99.2 EX-99.2

Exhibit 99.2

 

Contacts:

Alnylam Pharmaceuticals, Inc.

 

Christine Regan Lindenboom

(Investors and Media)

+1-617-682-4340

 

Josh Brodsky

(Investors)

+1-617-551-8276

    LOGO

Alnylam Announces Pricing of Offering of $900 Million Convertible Senior Notes

CAMBRIDGE, Mass. — September 13, 2022 — Alnylam Pharmaceuticals, Inc. (“Alnylam”) (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today the pricing of its previously announced private offering of $900 million aggregate principal amount of 1.00% convertible senior notes due 2027 (the “notes”) to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). In addition, Alnylam granted the initial purchasers of the notes an option to purchase, for settlement within a 13-day period beginning on, and including, the date on which the notes are first issued, up to an additional $135.0 million aggregate principal amount of the notes. The offering is expected to close on September 15, 2022, subject to customary closing conditions.

The notes will be senior, unsecured obligations of Alnylam and will accrue interest at a rate of 1.00% per annum, payable semi-annually in arrears on March 15 and September 15 of each year, beginning on March 15, 2023. The notes will mature on September 15, 2027, unless earlier converted, redeemed or repurchased. Before June 15, 2027, noteholders will have the right to convert their notes in certain circumstances and during specified periods. From and after June 15, 2027, noteholders may convert their notes at any time at their election until the close of business on the second scheduled trading day immediately before the maturity date. Alnylam will settle conversions by paying or delivering, as applicable, cash, shares of its common stock, par value $0.01 per share (“common stock”), or a combination of cash and shares of its common stock, at Alnylam’s election. The initial conversion rate is 3.4941 shares of common stock per $1,000 principal amount of the notes, which represents an initial conversion price of approximately $286.20 per share of Alnylam’s common stock. The initial conversion price represents a premium of approximately 35.0% above the last reported sale price of the Alnylam’s common stock on The Nasdaq Global Select Market on September 12, 2022, which was $212.00 per share.

The conversion rate and conversion price will be subject to adjustment upon the occurrence of certain events.

The notes will be redeemable, in whole or in part (subject to certain limitations), for cash at Alnylam’s option at any time, and from time to time, on or after September 20, 2025 and on or before the 21st scheduled trading day immediately preceding the maturity date, if the last reported sale price per share of Alnylam’s common stock exceeds 130% of the conversion price for a specified period of time. The redemption price will be equal to the principal amount of the notes to be redeemed, plus accrued and unpaid interest, if any, to, but excluding, the redemption date.

In connection with the pricing of the notes, Alnylam entered into privately negotiated capped call transactions with certain of the initial purchasers or their respective affiliates and certain other financial institutions (the “option counterparties”). The capped call transactions are expected generally to reduce potential dilution to Alnylam’s common stock upon conversion of any notes and/or offset any potential cash payments Alnylam is required to make in excess of the principal amount of converted notes, as the case may be, with such reduction and/or offset subject to a cap. The cap price of the capped call transactions will initially be $424.00 per share of Alnylam’s common stock, which represents a premium of 100% over the last reported sale price of Alnylam’s common stock on The Nasdaq Global Select Market on September 12, 2022.

Alnylam has been advised that, in connection with establishing their initial hedges of the capped call transactions, the option counterparties or their respective affiliates expect to purchase shares of Alnylam’s common stock and/or enter into various derivative transactions with respect to Alnylam’s common stock concurrently with or shortly after the pricing of the notes. This activity could increase (or reduce the size of any decrease in) the market price of Alnylam’s common stock or the notes at that time. In addition, the option counterparties or their respective affiliates may modify their hedge positions by entering into or unwinding various derivatives with respect to Alnylam’s common stock and/or purchasing or selling Alnylam’s common stock or other securities of Alnylam in secondary market transactions from time to time prior to the maturity of the notes (and are likely to do so during any observation period related to a conversion of notes). This activity could cause or avoid an increase or a decrease in the market price of Alnylam’s common stock or the notes, which could affect the ability of holders to convert the notes and, to the extent the activity occurs following conversion or during any observation period related to a conversion of notes, it could affect the amount and value of the consideration that holders will receive upon conversion of the notes.

Alnylam estimates that the net proceeds from the offering of the notes will be approximately $883.2 million (or approximately $1,015.8 million if the initial purchasers exercise their option to purchase additional notes in full), after deducting the initial purchasers’ discounts and estimated offering expenses payable by Alnylam. Alnylam intends to use approximately $103.1 million of the net proceeds from the offering to pay the cost of the capped call transactions. If the initial purchasers exercise their option to purchase additional notes, Alnylam expects to use a portion of the net proceeds from the sale of the additional notes to enter into additional capped call transactions. In addition, Alnylam intends to use approximately $762.0 million of the net proceeds from the offering to repay borrowings and accrued and unpaid interest, and to pay the prepayment premium, under and terminate its current credit agreement, and the remainder of the net proceeds for general corporate purposes.

The notes will be offered only to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act. The offer and sale of the notes and any shares of common stock issuable upon conversion of the notes have not been, and will not be, registered under the Securities Act or any other securities laws, and the notes and any such shares cannot be offered or sold absent registration or except pursuant to an applicable exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and any other applicable securities laws.

This press release does not constitute an offer to sell, or the solicitation of an offer to buy, the notes or any shares of common stock issuable upon conversion of the notes, nor will there be any sale of the notes or any such shares, in any state or other jurisdiction in which such offer, sale or solicitation would be unlawful.

About Alnylam Pharmaceuticals

Alnylam (Nasdaq: ALNY) has led the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of people afflicted with rare and prevalent diseases with unmet need. Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful, clinically validated approach yielding transformative medicines. Since its founding 20 years ago, Alnylam has led the RNAi Revolution and continues to deliver on a bold vision to turn scientific possibility into reality. Alnylam’s commercial RNAi therapeutic products are ONPATTRO® (patisiran), GIVLAARI® (givosiran), OXLUMO® (lumasiran), AMVUTTRA® (vutrisiran) and Leqvio® (inclisiran) being developed and commercialized by Alnylam’s partner, Novartis. Alnylam has a deep pipeline of investigational medicines, including multiple product candidates that are in late-stage development. Alnylam is executing on its “Alnylam P5x25” strategy to deliver transformative medicines in both rare and common diseases benefiting patients around the world through sustainable innovation and exceptional financial performance, resulting in a leading biotech profile. Alnylam is headquartered in Cambridge, MA.

Alnylam Forward Looking Statements

Various statements in this release concerning Alnylam’s future expectations, plans and prospects, including, without limitation, statements regarding: whether Alnylam will issue the notes; the anticipated use of the net proceeds from the offering; expectations regarding the effect of the capped call transactions; expectations regarding actions of the option counterparties and their respective affiliates; and whether the capped call transactions will become effective, constitute forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Actual results and future plans may differ materially from those indicated by these forward-looking statements as a result of various important risks, uncertainties and other factors, including, without limitation: the direct or indirect impact of the COVID-19 global pandemic or any future pandemic on Alnylam’s business, results of operations and financial condition and the effectiveness or timeliness of Alnylam’s efforts to mitigate the impact of the pandemic; the potential impact of the recent leadership transition on Alnylam’s ability to attract and retain talent and to successfully execute on its “Alnylam P5x25” strategy; Alnylam’s ability to discover and develop novel drug candidates and delivery approaches; the pre-clinical and clinical results for its product candidates; actions or advice of regulatory agencies and Alnylam’s ability to obtain and maintain regulatory approval for its product candidates, including patisiran and vutrisiran, as well as favorable pricing and reimbursement;

successfully launching, marketing and selling its approved products globally; delays, interruptions or failures in the manufacture and supply of its product candidates or its marketed products; obtaining, maintaining and protecting intellectual property; Alnylam’s ability to successfully expand the indication for ONPATTRO, AMVUTTRA or OXLUMO in the future; Alnylam’s ability to manage its growth and operating expenses through disciplined investment in operations and its ability to achieve a self-sustainable financial profile in the future without the need for future equity financing; Alnylam’s ability to maintain strategic business collaborations; Alnylam’s dependence on third parties for the development and commercialization of certain products, including Novartis, Sanofi, Regeneron and Vir; the outcome of litigation; the potential impact of current and the risk of future government investigations; and unexpected expenditures; as well as those risks more fully discussed in the “Risk Factors” filed with Alnylam’s most recent Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (“SEC”) and in its other SEC filings. In addition, any forward-looking statements represent Alnylam’s views only as of today and should not be relied upon as representing its views as of any subsequent date. Alnylam explicitly disclaims any obligation, except to the extent required by law, to update any forward-looking statements.

EX-101.SCH 4 alny-20220912.xsd XBRL TAXONOMY EXTENSION SCHEMA 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink EX-101.LAB 5 alny-20220912_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Cover [Abstract] Amendment Flag Amendment Flag Entity Central Index Key Entity Central Index Key Document Type Document Type Document Period End Date Document Period End Date Entity Registrant Name Entity Registrant Name Entity Incorporation State Country Code Entity Incorporation State Country Code Entity File Number Entity File Number Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Two Entity Address, City or Town Entity Address, City or Town Entity Address, State or Province Entity Address, State or Province Entity Address, Postal Zip Code Entity Address, Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre Commencement Tender Offer Pre Commencement Tender Offer Pre Commencement Issuer Tender Offer Pre Commencement Issuer Tender Offer Security 12b Title Security 12b Title Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name Entity Emerging Growth Company Entity Emerging Growth Company EX-101.PRE 6 alny-20220912_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 7 g397120dsp001.jpg GRAPHIC begin 644 g397120dsp001.jpg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g397120g0913091940911.jpg GRAPHIC begin 644 g397120g0913091940911.jpg M_]C_X 02D9)1@ ! 0$ 8 !@ #_VP!# @&!@<&!0@'!P<)"0@*#!0-# L+ M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7& MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$ P$! 0$! M 0$! 0 $" P0%!@<("0H+_\0 M1$ @$"! 0#! <%! 0 0)W $" M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$ MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4 MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,! (1 Q$ /P#W^BBB@ KC MO%/Q+T#PM*UM+*]W? :C%9R*C*S,1D[>PJRLBNJE3PXROO4 M-S807;JTJG'XKD5:2E9+".25)'7_O537-6@T+0[S5+D_NK:(R$?WCV'U)P/QJU:74-]:0 MW5NX>&5 Z,.X->6_$Z\N?$_B/3/ FEO\\CB>]<=(QU&?H,M_WS1&-Y68.2Y; MH7X-:7G1G,=LHGN2/7_EFGXD%O\ @(]:;]^38K\D M4NIJCITQ7"_$N[NKG3K+POIC[=1UN7R@0<;(E&YV..0.@_$UW5 ]=DU[PI;2W.1?6Q-K>*>HE M3@Y^O!_&NEK@(#_PBOQ7FMS\FG>)(O-C]%NHQ\P_X$O/U(KOZ4UK=!%Z6.'^ M'LDDFH^, \CN%UN8+N8G:,#@>@KN*X3X=?\ (2\9?]AR;^0JG_PEWB:Z\9:] MX=TJU@GGAEC%O-,NV&UCV99I".6))&%'OZ54HMR=A*5DCT>BO.]6?Q_X7L)- M9DU:QUJVMAYES9_8Q"VP?>*,#V'//ZUNZYJ^I7G@7^W/##H9S"MW$DD>[S4Q MEDQV.,_B*GD'S'3T5G:!K-MXAT*SU:T/[FYC#@=U/=3[@Y'X5BZIKU_+XZTS MP[I+QJ$C-WJ4C)NV0]%0>A8_I247>P[JURC822'XU:M&9',8TB(A-QV@[^N* M[FN#L/\ DM^K_P#8'A_]#K5UB/Q??ZJ]KI,]EI>G1JN;V6/SY96(Y"IP !ZF MJDKM>A*>C.GHK@?[3\3^%/$FDV>MZE;ZOIFJ3?9DG6V$,L,N,KD#@@_Y]]'X MB>(KSPQX=@U"R95;[9%')F/?F,D[@!ZX'%+D=TEU'S*USK:*X<0^/M<0WT6H MV6@PN-T%FUJ)Y0O;S6)P&]0.E9MAX[\0O/<>&9=*AF\5P2^7N7*VQBP#Y['J M%P1P.22,>SY'T#G74]*J">]MK:1(YID1G^Z":X/51\0O#VG2ZR=8T_58[93+ M<6(L_*!0\TEWTRYE,87$]HH'[U?4<9S[=Q^O645=.; MIR4ET,JU)58.#ZGC7AOQXOA72[R*^5I;5$:2 #JLG]SZ,?R-=3\-O#5S8VMS MXCUD;M;U=O.ESUBC/(3V[$_@.U8NL>$D\<^*+ZYTU8K6QL&\MI2IV7=T#\W M[+T)'5L]<&GVND^/]*'V6T>3R1PN)HW0?3=R*[ZBIU[RBU%O>YYM*57"I4YQ MM'AG39[#2O,O3NO[IS<73'^^W;Z M 8'X5@Z!X-O?[476/$5U]JNTYBCW;@I[$GIQV XKMZY:O)"/)!W[O]#LH^TJ M2]K45NR_5^?Y'*_$/79=#\)7!M,G4+QA9VBKU,C\#'T&3^%8NC_#S7](TFWL M;/QM=VL,:_ZF*TC*J3R<$\GDGDUHZCHFHZW\2M/O+NV*:)I$)E@8NI\ZX;OC M.1M&.O<5V=9\W*K(Z+7=V>6>+/ _B/\ L5]2/BNZU*ZTP_;+:&2VC3YTYX*\ MYQGZUZ!X>UF'Q#X?L=6M\>7=1!\#^%OXA^!R/PK3(!&",@UQG@C1=2\,ZEK> MDR6Y_L4W!N=.F#@@!^6CQG(P?;UI-\T=>@6L]"O\.O\ D)>,?^PY-_(4[P=_ MR/\ XZ_Z^;;_ -%FKG@K1[_2K[Q-)>V_E+>:K)<0'<#OC(&#P>/QI?#6D7]A MXP\67US!Y=M?3P/;/N!WA4(/ .1SZU3:U_KL))Z&[K@#>']24C(-K*"/^ &L M'X8Y/PUT'/\ S[?U-=%JD,EQI%[!$NZ22!T1<]25(%9'@/3;O1_ VD:??P^3 M=00;)(]P.TY/<<5'V2OM'+6%_!\.?%6KZ5>OY6B7D(]23;J6N2_:74]8XND2?0+S^-9_CJSMO%GBO0O"WDK)Y+G4+V M7',4(X"Y[;SQ^ KT)5"J%4 *!@ #@54GIYLF*U]#A+#_ )+=J_\ V!X?_0ZN M:KXJU.Y\0S>'O"]C!=7MNJM>75TY6"VW= <CW\7Q4U+6'MR-/ MFTR.".;<.7#Y(QG/3VK)^SZ]X.\6ZS?V6B2ZSIFKR+.?LTBK+!(!@@AB,BGH MW\@U2,SQ19>([?5_";&2%QGU.<4^L;B[V.ZK@],4#XV:Z0 M.NE0$_\ ?5=Y7)6.CW\7Q2U75WM\6$^G10QR[A\SALD8SG]*SB]RY=#HM4 ; M2+U2,@P."/\ @)KF?A5_R3+0_P#KDW_HQJZF^C>;3[F*,9=XF51ZD@XK"^'V MEWNB^!-*T[4(?)NX(V$D>X-M)=CU''0BC[(?:.EHHHJ2@K.U8W4T L;&0Q7% MQ\IG'_+%/XG'OV'N1V!K1HP,YQS0!6L+&VTRP@L;.(16\"!$0=A_4^I[U9HH MH **** "BBB@ HHHH **** "H+Z\@TZPN+VY?9!!&TDC>@ R:GHH X#PE;WP MT'5?%MU&R:KK+>>BL.8H1Q$G/^SS^-=,+K5()4BDB$[F&1R RC&&&W)Q@G!Y MQQ6S15.5V2HV1AV^JW;W5GNB8VYB1)WV# E=01WSQP.G\?M5:VU#59+50T@2 M=V@:/S$#95OO?= X)X]1^5=+12N.Q@27^JK%<1",&\:8"*.-0PC78K$9.-WI MGCEJFBU$75T3)>FT3$9AB(4&0$ G.X<\Y7 Z8]ZV:3 SG'3I1<+&'%J2W(K M9P/2CH,"BX6,:YO+B*:2)IS'"LT<;3E!E%*9)Z8Y; R1@9IMSJ4T!M_LLCW< M,>9+B955OW>2.HP/4\#^#'>MNCH,"BX6,:34)&L+O9=0)<0S,OS.JE4#X[Y B)' )&,D5I64XN;*"8;\2(&_> !NG?''Y5-@>@YZTM '_V0$! end XML 9 R1.htm IDEA: XBRL DOCUMENT v3.22.2.2
Document and Entity Information
Sep. 12, 2022
Cover [Abstract]  
Amendment Flag false
Entity Central Index Key 0001178670
Document Type 8-K
Document Period End Date Sep. 12, 2022
Entity Registrant Name Alnylam Pharmaceuticals, Inc.
Entity Incorporation State Country Code DE
Entity File Number 001-36407
Entity Tax Identification Number 77-0602661
Entity Address, Address Line One 675 West Kendall Street
Entity Address, Address Line Two Henri A. Termeer Square
Entity Address, City or Town Cambridge
Entity Address, State or Province MA
Entity Address, Postal Zip Code 02142
City Area Code (617)
Local Phone Number 551-8200
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Security 12b Title Common Stock, $0.01 par value per share
Trading Symbol ALNY
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
XML 10 d397120d8k_htm.xml IDEA: XBRL DOCUMENT 0001178670 2022-09-12 2022-09-12 false 0001178670 8-K 2022-09-12 Alnylam Pharmaceuticals, Inc. DE 001-36407 77-0602661 675 West Kendall Street Henri A. Termeer Square Cambridge MA 02142 (617) 551-8200 false false false false Common Stock, $0.01 par value per share ALNY NASDAQ false EXCEL 11 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0 ( +R +54'04UB@0 +$ 0 9&]C4')O<',O87!P+GAM M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGDK7A.YNJQ<&4GPZ4A!0W_J=0U[R;UEA_6\#MI7E!+ P04 M " "\@"U58!YLJN\ K @ $0 &1O8U!R;W!S+V-O&ULS9+! M:L,P#(9?9?B>R$EH82;U9:6G#08K;.QF;+4UBV-C:R1]^R5>FS*V!]C1TN]/ MGT"M#D+[B,_1!XQD,=V-KNN3T&'#3D1! "1]0J=2.27ZJ7GPT2F:GO$(0>D/ M=42H.5^#0U)&D8(96(2%R&1KM- 1%?EXP1N]X,-G[#+,:, .'?:4H"HK8'*> M&,YCU\(-,,,(HTO?!30+,5?_Q.8.L$MR3'9)#<-0#DW.33M4\/;T^)+7+6R? M2/4:IU_)"CH'W+#KY-?F8;O?,5GSNB[X?5$U^YH+OA*K]?OL^L/O)NR\L0?[ MCXVO@K*%7W&UL[5I;<]HX%'[OK]!X9_9M"\8V@;:T$W-I=MNTF83M M3A^%$5B-;'EDD81_OTV23;J;/ 0LZ?O.14?GZ#AY\^XN8NB&B)3R M> +]O6N[!3+ MUES@6QHO(];JM-O=5H1I;*$81V1@?5XL:$#05%%:;U\@M.4?,_@5RU2-9:,! M$U=!)KF(M/+Y;,7\VMX^9<_I.ATR@6XP&U@@?\YOI^1.6HCA5,+$P&IG/U9K MQ]'22(""R7V4!;I)]J/3%0@R#3LZG5C.=GSVQ.V?C,K:=#1M&N#C\7@XMLO2 MBW A(5M>5 TR M6'!VULS2 Y9>*?IUE!K9';O=05SP6.XYB1'^QL4$UFG2&98T1G*=D 4. #?$ MT4Q0?*]!MHK@PI+27)#6SRFU4!H(FLB!]4>"(<7K;YH] M5Z%82=J$^!!&&N*<<^9ST6S[!Z5&T?95O-RCEU@5 9<8WS2J-2S%UGB5P/&M MG#P=$Q+-E L&08:7)"82J3E^34@3_BNEVOZKR2.FJW"$2M"/F(9 M-AIRM1:!MG&IA&!:$L;1>$[2M!'\6:PUDSY@R.S-D77.UI$.$9)>-T(^8LZ+ MD!&_'H8X2IKMHG%8!/V>7L-)P>B"RV;]N'Z&U3-L+([W1]072N0/)J<_Z3(T M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+ M.7\N?<^E[[GT/:'2MSAD6R4)RU3393>* M$IY"&V[I4_5*E=?EK[DHN#Q;Y.FOH70^+,_Y/%_GM,T+,T.WF)&Y M"M-2D&_#^>G%>!KB.=D$N7V85VWGV-'1^^?!4;"C[SR6'<>(\J(A[J&&F,_# M0X=Y>U^89Y7&4#04;6RL)"Q&MV"XU_$L%.!D8"V@!X.O40+R4E5@,5O& RN0 MHGQ,C$7H<.>77%_CT9+CVZ9EM6ZO*7<9;2)2.<)IF!-GJ\K>9;'!51W/55OR ML+YJ/;053L_^6:W(GPP13A8+$DACE!>F2J+S&5.^YRM)Q%4XOT4SMA*7&+SC MYL=Q3E.X$G:V#P(RN;LYJ7IE,6>F\M\M# DL6XA9$N)-7>W5YYNTB42%(JP# 4A M%W+C[^^3:G>,U_HL@6V$5#)DU1?*0XG!/3-R0]A4)?.NVB8+A=OB5,V[&KXF M8$O#>FZ=+2?_VU[4/;07/4;SHYG@'K.' MYA,L0Z1^P7V*BH 1JV*^NJ]/^26<.[1[\8$@F_S6VZ3VW> ,?-2K6J5D*Q$_ M2P=\'Y(&8XQ;]#1?CQ1BK::QK<;:,0QY@%CS#*%F.-^'19H:,]6+K#F-"F]! MU4#E/]O4#6CV#30,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04 M" "\@"U5_2&?BG$$ !+$0 & 'AL+W=O92W(TT&;:3E\(>P'-R99/ED/X M]ET98J=7L^8-6+;T^"=I]:SDX5:;K]D&P++76"79R-M8FUZVVUFX@5AD+9U" M@D]6VL3"8M&LVUEJ0$1%HUBU ]_OM6,A$V\\+.[-S'BH]MQM/69U?&B,!+%,]O_B]3 0IS0(#@V"@GO_HH+R6E@Q'AJ]9<;51C5W472U:(UP M,G&S,K<>IL9\?7.LQQD"T32<1N$BOMCMTE^]G&41NV+;[$56V'!\&KO6!P M1' .:8OQX(P%?A#\MWD;V4K H 0,"KV+(WI3_0*&_3U99M;@%/Y31[17Z-0K MN+B^S%(1PLC#P,W O( W_ND'WO-_)?@N2KX+2GT\P=&+BA&\56)=1T>W7PF5 M <'1*3DZI,YA[J9(8H3".8S@E7V&71T1K>3[/N?]0:_O$UC=$JM+BI7QM=BE M4,="-Q^B5$[S2(&1BI79Q'#%=++0^M5$9W4WCW2[3^*=/V!&OI AP9 M'T5<"T;K3%2R4R)FLXW I1M";F6(D76&@1"V",Y!R3DXA1/5M$FU*"T\/4-0?>AI/MP"MVM5, >\W@)I@Z$UL"H/[_H=?P^PO\N>(;/H.TDDE,( ,9B8*-PJ#7#2Q6G=NI(V;*&W]4F5EIN*>&EDM";AJE3! M3\H5)=Q^'2/=S.@7F83U;Z91%.FW\QAQ/<^QY'H05^[O'^+Q1*E34X;??W&MT=S5XGE.$UB'2[_'R MVW>*J,H/G/;Q9R.MA02')H[SY&!V62T5+=2T(>)54N"TH\^UDJ&T,EFS!PQP M(X6JY:%5FGB"*B<$M('/#!3# [C"]GLBM$FTG2^K5?W\->@UDE6Y(*"-^W]D M=UF6(UDC("W;"/CN$$!;]1S"W+CEQX,E6TBK:I=?@XCK8;%KT>'7,_:CW_(Y M2X5A+T+EP%+L:+:A_3^H_#^@#7MA1.0";[Z+E[HV[!H$)O>/?U(DE=D'M#&7 M0W?S&FY$LH:C.\P&H9X4&X-V9,P0J%_%8?=6QEO%D MN7/ZZZ>S;"=I=67=A['-HN6/O.-%Q[I#)6,>=56R=M8SDK6W!2,EG>W&2)8D+38JT[=:=<2PZFTVY# M;VA2K"NCSY:4!H-?RA0GCTQNZ)9)L;=B6,N4D*=@7H+A8*2QQ'DJ?$,78&F? M KP(&K XU7=>&18/QA<0 M&>7=J?$,:\M.B^4M/3L,/S[)WMB2VSG-@DZF8BUY!72LJ(_PZTR3 .B<45XH M!:N-9@.'R6,4?-@#E_(!6OBMNHK=5R3TXE,);2"PU4GTA$8QA D*Q+^,%F)? MA+W]K;"D$8_&?>S\;O2@?^^,X_>65Z(?]+Z:\V/1%WATUC3R]$&*6BL>]O[+ M"8LUF_S(T5CQY+/!I!R\@5M*'KEUXG!I^6%9L^.]FZ:IKW#.RW^0\Y^M<\TU MMTQ>DO:C_S=7^2V,D_'T7!S1JP,Z6PEY7>>9 ]IV03NA1.XJRY/K% M.?7A'=O["_PJOE]?\HIUTNUF<$//\A=>BD[E\ZI[J,NXZBQ_AOMHD\%G'!QR>(W?#$T%^@2O&+(=/EB>N$_NG_A.\SQ-LPRKZ'8;9;#%ZI9E\!>/AG$# M#RP/9'I;K?%NXQ/R^AQ@/7UM0K"=XI.([12O-2#QNH%'GL>[C>4!#ZP+V.Q M_G@>F*FX3YI"5S%NV G&D3S'$)C%^(QF&5*=##[Q_F"G)$WS/(X %F>0IA@" MIQ%', ; 4/2='@//GL?)=-[*CG_5U/\!%!+ P04 " "\@"U5EXJ[', M 3 @ "P %]R96QS+RYR96QSG9*Y;L,P#$!_Q=">, ?0(8@S9?$6!/D! M5J(/V!(%BD6=OZ_:I7&0"QEY/3P2W!YI0.TXI+:+J1C]$%)I6M6X 4BV)8]I MSI%"KM0L'C6'TD!$VV-#L%HL/D N&6:WO606IW.D5XA-/E_G;@2=&A(E@6FD7)TZ(=I7\= MQ_:0T^FO8R*T>EOH^7%H5 J.W&,EC'%BM/XU@LD/['X 4$L#!!0 ( +R M+54<.&7J/P$ #P" / >&PO=V]R:V)O;VLN>&ULC5'+;L) #/R5U7Y M$U"+5$2XE#Z0JA:5BON2=8C%/B*O RU?7R=15*1>>O)Z;(UG9A?G2,=]C$?U MY5U(A:Z9FWF6I;(&;])-;"#(I(KD#4M+ARPU!,:F&H"]RZ9Y/LN\P:"7BY%K M0]EU$QE*QA@$[( =PCG]SKM6G3#A'AWR=Z'[MP.M/ ;T> %;Z%RK5,?S2R2\ MQ,#&;4N*SA5Z,@QV0(SE'WC;B?PT^]0C;/8?1H04>I8+8864N-_H^8UH/($L M#UW+\0D= ZT,PS/%ML%PZ&C$179EH\]AK$.(<_I/C+&JL(15+%L/@8<<"5PG M,*0:FZ15,!X*/:XH$ZQZ#"PAJ748J&2WEYIK=WDWM)J'7N0;#W\!J-'[IFBG#S^0W1UW6E\./VR./ /,+Q=Z*E%9"E*%1KD3,)HMC;!4N++ M3):BJ#(9BBJ6<%H@XLD@;6E6?;!/3K3G>1,)KM\,<'AT_@%02P,$ M% @ O( M5660>9(9 0 SP, !, !;0V]N=&5N=%]4>7!E&UL MK9--3L,P$(6O$F5;)2XL6*"F&V +77 !8T\:J_Z39UK2VS-.VDJ@$A6%3:QX MWKS/GI>LWH\1L.B=]=B4'5%\% )5!TYB'2)XKK0A.4G\FK8B2K636Q#WR^6# M4,$3>*HH>Y3KU3.T.EY&TWP39G 8ED\C<+,:DH9HS5*$M?%P>L?E.I$ MJ+EST&!G(BY84(JKA%SY'7#J>SM 2D9#L9&)7J5CE>BM0#I:P'K:XLH90]L: M!3JHO>.6&F,"J;$#(&?KT70Q32:>,(S/N]G\P68*R,I-"A$YL01_QYTCR=U5 M9"-(9*:O>"&R]>S[04Y;@[Z1S>/]#&DWY(%B6.;/^'O&%_\;SO$1PNZ_/[&\ MUDX:?^:+X3]>?P%02P$"% ,4 " "\@"U5!T%-8H$ "Q $ M @ $ 9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0 ( +R +55@ M'FRJ[P "L" 1 " :\ !D;V-0&UL4$L! A0#% @ O( M5?TAGXIQ! M2Q$ !@ ("!#@@ 'AL+W=O81 !X M;"]?7!E&UL 64$L%!@ ) D /@( !44 $! end XML 12 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 13 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 14 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.2.2 html 1 23 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://www.alnylam.com//20220912/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports d397120d8k.htm alny-20220912.xsd alny-20220912_lab.xml alny-20220912_pre.xml d397120dex991.htm d397120dex992.htm http://xbrl.sec.gov/dei/2021 true false JSON 16 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "d397120d8k.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "d397120d8k.htm" ] }, "labelLink": { "local": [ "alny-20220912_lab.xml" ] }, "presentationLink": { "local": [ "alny-20220912_pre.xml" ] }, "schema": { "local": [ "alny-20220912.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.sec.gov/dei/2021/dei-2021.xsd", "https://xbrl.sec.gov/naics/2021/naics-2021.xsd" ] } }, "elementCount": 24, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 23, "memberCustom": 0, "memberStandard": 0, "nsprefix": "alny", "nsuri": "http://www.alnylam.com/20220912", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "p", "div", "div", "body", "html" ], "baseRef": "d397120d8k.htm", "contextRef": "duration_2022-09-12_to_2022-09-12", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document and Entity Information", "role": "http://www.alnylam.com//20220912/taxonomy/role/DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "div", "div", "body", "html" ], "baseRef": "d397120d8k.htm", "contextRef": "duration_2022-09-12_to_2022-09-12", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.alnylam.com//20220912/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.alnylam.com//20220912/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.alnylam.com//20220912/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.alnylam.com//20220912/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.alnylam.com//20220912/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two", "terseLabel": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.alnylam.com//20220912/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.alnylam.com//20220912/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.alnylam.com//20220912/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.alnylam.com//20220912/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.alnylam.com//20220912/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.alnylam.com//20220912/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.alnylam.com//20220912/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation State Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.alnylam.com//20220912/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.alnylam.com//20220912/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.alnylam.com//20220912/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.alnylam.com//20220912/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre Commencement Issuer Tender Offer", "terseLabel": "Pre Commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.alnylam.com//20220912/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre Commencement Tender Offer", "terseLabel": "Pre Commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.alnylam.com//20220912/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Security 12b Title", "terseLabel": "Security 12b Title" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.alnylam.com//20220912/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.alnylam.com//20220912/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.alnylam.com//20220912/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.alnylam.com//20220912/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.alnylam.com//20220912/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r5": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" } }, "version": "2.1" } ZIP 17 0001193125-22-243702-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-22-243702-xbrl.zip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